mRNA Vaccine & Therapeutics Market to Reach $850.9M by 2033, Driven by AI & Oncology Breakthroughs | DataM Intelligence

NEW YORK, NY, UNITED STATES, June 20, 2025 /EINPresswire.com/ -- The mRNA Vaccine and Therapeutics Market is undergoing a transformative shift, evolving beyond its role in infectious disease prevention to revolutionize personalized medicine, oncology, and rare disease treatment. Originally propelled into the spotlight by COVID-19 vaccines, mRNA technology has demonstrated unparalleled flexibility, speed, and efficacy in targeting specific genetic instructions. In 2024, the global mRNA vaccine and therapeutics market reached a valuation of US$ 410 million and is projected to grow to US$ 850.90 million by 2033, expanding at a CAGR of 8.5% from 2025 to 2033.

Get Latest Sample Report Pdf : https://datamintelligence.com/download-sample/mrna-vaccine-and-therapeutics-market

Market Drivers are :

Post-COVID momentum: The success of mRNA vaccines during the pandemic accelerated global investment and regulatory acceptance.

Rising chronic and infectious diseases: Growing global burden of cancer, HIV, Zika, and other infectious diseases is fueling demand for tailored mRNA therapies.

Rapid development cycles: mRNA platforms offer shorter development timelines compared to traditional vaccines and biologics.

Strong pipeline activity: Ongoing clinical trials for cancer immunotherapies, rare diseases, and flu vaccines are expanding market scope.

Collaborative ecosystem: Partnerships between biotech firms and research institutions are enhancing delivery platforms and manufacturing capacity.

Regulatory support: Streamlined pathways and emergency approvals are driving innovation and commercial momentum.

Key Players in the Market are :

Prominent players shaping the mRNA vaccines and therapeutics market include:

Azra AI

CureMetrix, Inc.

ConcertAI

Immunai

MVision AI Inc.

Paige AI, Inc.

Mindpeak GmbH

Imagene AI Ltd.

Predictive Oncology

Tempus

These companies are spearheading development in AI-assisted mRNA drug design, immunotherapy pipelines, cancer diagnostics, and delivery technologies.

Market Segmentation :

By Application

Infectious Diseases
Oncology
Rare Genetic Disorders
Autoimmune Diseases
Others

By Route of Administration

Intramuscular
Intravenous
Subcutaneous
Others

By End User

Hospitals
Research Laboratories
Biopharmaceutical Companies
Academic Institutes

Latest News from the USA -

In April 2024, Moderna announced positive interim results from its phase II trial of an mRNA-based melanoma vaccine developed in collaboration with Merck, showing a reduced recurrence rate.

The U.S. FDA fast-tracked approval for a new mRNA-based RSV vaccine targeting adults aged 60 and above, following successful multi-center trials.

Tempus secured a new federal grant to integrate AI-driven analytics into the development of mRNA therapeutics for rare pediatric diseases.

Latest News from Japan -

In February 2024, Takeda Pharmaceuticals partnered with Kyoto University to launch a new mRNA research hub focused on next-gen cancer vaccines in Japan.

The Japanese Ministry of Health introduced regulatory reforms to accelerate clinical trial approval for innovative RNA-based therapeutics.

RIKEN Institute reported promising results from a joint project testing mRNA vaccines for pancreatic cancer in preclinical models.

Key Developments are :

Azra AI released an upgraded AI platform to streamline identification of oncology candidates for mRNA therapeutic trials.

CureMetrix announced a collaboration with a U.S.-based hospital network to integrate AI-assisted diagnostic tools into mRNA vaccine trial evaluations.

ConcertAI unveiled a data analytics platform for real-world evidence generation to support mRNA oncology studies.

Immunai expanded its single-cell platform to better understand immune response in mRNA-based cancer therapies.

Mindpeak GmbH secured funding to improve precision diagnostics for mRNA-based breast cancer treatments using deep learning algorithms.

Conclusion :

The mRNA vaccines and therapeutics market is entering a new era of possibility, extending its influence far beyond COVID-19 into oncology, rare diseases, and autoimmune disorders. Fueled by innovation, data-driven platforms, and collaborative R&D, the field is moving toward more precise, scalable, and effective treatments. As clinical validation strengthens and regulatory frameworks evolve, the market is well-positioned to redefine healthcare delivery through fast, targeted solutions with wide-reaching global benefits. Over the next decade, mRNA will likely remain at the forefront of medical innovation, catalyzing advancements in both prevention and therapy.

Browse for Related Reports :

RNAi Therapeutics Market

Muscle Spasticity Market

Sai Kumar
DataM Intelligence 4market Research LLP
+1 877-441-4866
email us here
Visit us on social media:
LinkedIn
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.